Clinical Trial Update: IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. [Phase 3]

View source ↗

Summary

A Phase 3 randomized pragmatic trial named IMPACT-AML is investigating relapsed or refractory acute myeloid leukemia and is currently recruiting. Sponsor is Ist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Acute Myeloid Leukemia, Relapse/Recurrence | Phase 3 | Status: RECRUITING